AstraZeneca PLC Ordinary Shares (AZN)

Total Costs & Expenses

$12.22B

Quarterly · Period ending: · USD

AZN logo

AZN Total Costs & Expenses

Latest reported$12.22B
AZN Quarterly Total Costs & Expenses ($1.75B → $12.22B)
High-resolution chart · PNG

AZN total costs & expenses history

Quarterly · USD. Dates are reporting period ends; fiscal years can differ from calendar years.

AstraZeneca PLC Ordinary Shares Total Costs & Expenses — Quarterly (USD)
Period endingTotal Costs & Expenses (USD)
12,220,000,000
11,042,000,000
12,525,000,000
11,608,000,000
10,949,000,000
9,914,000,000
12,855,000,000
11,459,000,000
10,192,000,000
9,564,000,000
10,790,000,000
9,538,000,000
8,960,000,000
8,330,000,000
10,113,000,000
9,737,000,000
10,232,000,000
10,512,000,000
12,303,000,000
11,540,000,000
7,093,000,000
5,425,000,000
5,923,000,000
5,407,000,000
4,991,000,000
5,134,000,000
6,087,000,000
5,649,000,000
5,330,000,000
4,394,000,000
5,340,000,000
4,489,000,000
4,392,000,000
4,482,000,000
5,091,000,000
5,083,000,000
4,126,000,000
4,488,000,000
3,052,000,000
4,671,000,000
5,300,000,000
5,077,000,000
5,311,000,000
4,775,000,000
5,384,000,000
5,124,000,000
7,032,000,000
6,068,000,000
5,653,000,000
5,624,000,000
7,435,000,000
4,544,000,000
5,032,000,000
4,988,000,000
5,318,000,000
4,526,000,000
4,792,000,000
5,189,000,000
6,489,000,000
3,951,000,000
5,465,000,000
4,891,000,000
6,206,000,000
5,492,000,000
5,144,000,000
4,933,000,000
6,620,000,000
4,996,000,000
5,107,000,000
4,538,000,000
6,301,000,000
5,253,000,000
5,483,000,000
5,420,000,000
6,241,000,000
5,128,000,000
5,300,000,000
4,796,000,000
5,151,000,000
4,410,000,000
4,494,000,000
4,204,000,000
4,650,000,000
4,094,000,000
4,414,000,000
4,290,000,000
8,760,000,000
4,093,000,000
4,236,000,000
4,022,000,000
4,026,000,000
3,682,466,544
3,560,825,908
3,468,707,547
3,985,690,674
3,370,583,868
3,248,000,000
3,049,000,000
8,796,206,462
2,935,000,000
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.